UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  June 7, 2011
 
Obagi Medical Products, Inc.
(Exact name of registrant as specified in its charter)
  
001-33204
(Commission File Number)
  
Delaware
  
22-3904668
(State or other jurisdiction of incorporation)
  
(I.R.S. Employer Identification No.)
 
3760 Kilroy Airport Way, Suite 500, Long Beach, CA 90806
 (Address of principal executive offices, with zip code)
  
(562) 628-1007
(Registrant’s telephone number, including area code)
Not applicable
 (Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 
 
 
□      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
□      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
□      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
□      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
 
 

 
 Item 5.07  Submission of Matters to a Vote of Security Holders.

(a)  
Obagi Medical Products, Inc. (the “Company”) held its 2011 Annual Meeting of Stockholders (the “2011 Annual Meeting”) on June 7, 2011.


(b)  
Proposal 1: At the 2011 Annual Meeting, the stockholders elected each of the nominees listed below as directors, to serve on the Company’s Board of Directors until the next annual meeting of stockholders and/or until their successors are duly elected and qualified. The vote for each director was as follows:

 
Total Affirmative Votes
Total Withheld Votes
Total Broker Non-Votes
    Albert F. Hummel
11,799,430
4,535,847
938,631
    Albert J. Fitzgibbons III
11,490,782
4,844,495
938,631
    Ronald P. Badie
 9,600,678
6,734,599
938,631
    John A. Bartholdson
11,491,302
4,843,975
938,631
    John H. Duerden
11,491,352
4,843,925
938,631
    Edward A. Grant
11,491,552
4,843,725
938,631


(c)  
Proposal 2:  At the 2011 Annual Meeting, the stockholders voted to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011. The vote on this proposal was as follows:

    Votes For
15,099,051
    Votes Against
     267,590
    Abstentions
  1,907,267
    Broker Non-Votes
Not applicable
 
   
(d)  
Proposal 3:  In addition, at the 2011 Annual Meeting, the stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to Item 4.02 of Regulation S-K in the “Compensation Discussion and Analysis” section, compensation tables and other narrative disclosures in the proxy statement for the 2011 Annual Meeting. The vote on this proposal was as follows:
          
    Votes For
14,301,387
    Votes Against
     217,585
    Abstentions
  1,816,305
    Broker Non-Votes
     938,631


(e) 
Proposal 4:  Finally, at the 2011 Annual Meeting, the stockholders voted to conduct an advisory vote on the frequency of future advisory votes on executive compensation.  The vote on this proposal was as follows:
      
    One Year
13,528,987
    Two Years
     132,188
    Three Years
  2,372,231
    Abstentions
     301,871
    Broker Non-Votes
     938,631



 
 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
OBAGI MEDICAL PRODUCTS, INC.
  
       
Date: June 7, 2011
By:
 /s/ Preston S. Romm   
   
Preston S. Romm
  
   
Chief Financial Officer